Dr. Paula James

Dr. Paula James MD, FRCPC

 

Departments of Medicine and Pathology
& Molecular Medicine 
Etherington Hall, Room 2025
Queen's University
Kingston, Ontario
K7L 2V6, CANADA

TEL: (613) 533-2946
FAX: (613) 533-6855
e-mail: jamesp (at) queensu.ca


Position

Associate Professor, Department of Medicine, Divison of Hematology
Cross-Appointment, Department of Pathology and Molecular Medicine
Cross-Appointment, Department of Pediatrics

Other Positions

Chair of the Research Advisory Committee of the Canadian Hemophilia Society
Co-Chair of the von Willebrand Factor Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH)

Medical Director of the Inherited Bleeding Disorders Clinic of Southeastern Ontario
Medical Director of the Women and Bleeding Disorders Clinic – Kingston General Hospital
Co-Director National Hemophilia Mutation Detection Program - Responsible for VWD genetic testing
Member of the ISTH SSC von Willebrand Factor Mutation Database Steering Committee

Scholarly Activities

Editorial Board of Haemophilia
Member of Global Emerging Hemophilia Expert Panel (GEHEP) - sponsored by Bayer Inc.

Education

Degree - M.D., University of Saskatchewan

Postgraduate Medical Training
PGY 4 & 5 Hematology, Queen's University
PGY 1 - 3 Internal Medicine, University of Saskatchewan

Postdoctorial Research Training
Fellow
- Clinical Investigator Program of The Royal College of Physicians and Surgeons of Canada - Molecular Hemostasis
- Department of Pathology, Queen's University - Supervisor: Dr. David Lillicrap

Scholarships and Awards

2012 Basmajian Award for Excellence in Health Sciences Research – Queen’s University
2011 Researcher of the Year Award of Excellence – National Hemophilia Foundation
2011 Clinician Scientist Development Program Award – Southeastern Ontario Medical Organization
2008 Aesculapian Society Queen’s Medical School Phase IIA Teaching Award
2008 CSL Behring Prof. Heimburger Award – Early Career Investigator Award
2007 Excellence in Research Award, Department of Medicine Queen’s University
2007 Bayer International Hemophilia Awards – Early Career Investigator Award
2005 Young Investigator Award – International Society of Thrombosis and Hemostasis
2003 John H. Crookston Award – Canadian Hematology Society
2003 Aventis Behring – CHS – AHCDC Fellowship
2002 Aventis Behring – CHS – AHCDC Fellowship
2000 Ian Holmes Senior Professionalism Award, University of Saskatchewan



Research Interests

Our primary research interest is focused on investigating the genotype/phenotype interactions in all subtypes of von Willebrand disease and in Hemophilia. Our projects not only examine the molecular genetic basis of these inherited bleeding disorders, but the impact of these disorders clinically as well. We are also particularly interested in the quantitation of bleeding symptoms and understanding correlations between bleeding scores and the molecular basis of disease. Our program strives to achieve a "bench-to-bedside" perspective; translating our basic science research into clinically useful data.


Dr. Paula James Research Group
Kingston, ON - June 2013



Selected Publications
(Past 5 Years)

Peer- reviewed:

Rydz N, Grabell J, Lillicrap D, James PD. 
Changes in von Willebrand factor level and activity with age in Type 1 von WIllebrand Disease.  Accepted by Haemophilia February, 2015.

Fogarty P, Mancuso ME, Kasthuri R, Bidlingmaier C, Chitlur M, Gomez K, Holme P, James P, Kruse-Jarres R, Mahlangu J, Mingot-Castellano ME, Soni A.
Presentation and Management of Acute Coronary Syndromes Among Adult Persons with Haemophilia: Results of an International, Retrospective, 10-year Survery.
Accepted to Haemophilia January 2015

Avila M, Lee J, Bouskill V, Rand M, James P, Carcao M. Acquired von Willebrand Syndrome in Pediatric Patients with Congenital Heart Disease: Challenges in the Diagnosis and Management of this Rare Condition.
Haemophilia. 2015 Jan;21(1):e89-92. doi: 10.1111/hae.12567. Epub 2014 Dec 11.  PMID: 25495773

Moorehead PC, Thibeault L, Tuttle A, Grabell J, Dwyre L, Silva M, James P, Lillicrap D.
Rapid Acquisition of Immunologic Tolerance to Factor VIII and Disappearance of Anti-Factor VIII IgG4 After Prophylactic Therapy in a Hemophilia A Patient With High-titer Factor VIII Inhibitor.
J Pediatr Hematol Oncol. 2014 Nov 19. [Epub ahead of print] PMID: 25411864

James P, Salomon O, Mikovic D, Peyvandi F.
Rare bleeding disorders-bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency.
Haemophilia 2014 May; 20 (Suppl 4):71-5.  PMID: 24762279

Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Clark D, Mauer A, Bowman M, Riddel J, Christopherson P, Montgomery R, Zimmerman Program Investigators, Rand M, Coller B, James PD.
Normal Range of Bleeding Scores for the ISTH-BAT: Adult and Pediatric Data from The Merging Project.
Haemophilia 2014 Nov;20(6): 831-5.  PMID: 25196510

Lee A, Sinclair G, Valentine K, James P, Poon M-C.
Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status. 
Blood 2014 Jul 31; 124(5):e1-3.  PMID: 24951428

James P.
Can bleeding score predict the risk of future bleeding? No BS here!
Blood 2014 Jun 26; 123(26):4008-9.  PMID: 24970927

Holden R, Booth S, Tuttle A, James P, Morton A, Hopman W, Nolan R, Garland J.
Sequence variation in vitamin K epoxide reductase gene is associated with survival and progressive coronary calcification in chronic kidney disease.
Arterioscler Thromb Vasc Biol 2014 July; 34(7):1591-6.  PMID: 24855061

Maceachern K, Kaur H, Toukh M, Mumal I, Hamilton A, Scovil S, James P, Elbatarny HS, Othman M.
Comprehensive Evaluation of Hemostasis in Normal Women: Impact on the Diagnosis of Mild Bleeding Disorders.
Clin Appl Thromb Hemost. 2015 Jan;21(1):72-81. PMID: 24715368

Kaur H, Ozela M, Scovil S, James PD, Othman M
Systematic analysis of bleeding phenotype in PT-VWD compared to type 2B VWD using an electronic bleeding questionnaire.
Clin Appl Thromb Hemost 2014 Nov;20(8):765-71. doi:10.1177/1076029614543825.  Epub 2014 Jul 25. PMID: 25063765

Mollah SA, James PD, Grabell J, Barbour EM, Coller B.
Diagnostic Prediction of von Willebrand Disease using Multiple Bleeding Phenomics Datasets.
AMIA Jt Summits Transl Sci Proc. 2013 Mar 18;2013:184. PMID 24273489

Rydz N, Leggo J, Tinlin S, James P, Lillicrap D. 
The Canadian “National Program for Hemophilia Mutation Testing” database: a ten-year review.
Am J Hematol Dec 2013; 88(12):1030-4. PMID: 23913812

Rydz N, Goodyear D, James PD.
The Clinical Diagnosis of Mild von Willebrand Disease. 
Int Monit VWD 2013 May: 9 – 12.

Sim Yan, Bowman M, Hopman W, Engen D, Silva M and James PD
Predicting Operative Bleeding in Elective Pediatric Surgeries using the Pediatric Bleeding Questionnaire (PBQ). 
J Ped Hematol Oncol  2014 May; 36(4) [PubMed-in process] PMID: 23774159

Kahlon A, Grabell J, Tuttle A, Engen D, Hopman W, Lillicrap D and James PD. 
Quantitation of Peri-operative Changes in von Willebrand Factor and Factor VIII During Elective Orthopedic and Cardiac Surgery in Normal Individuals. 
Haemophilia 2013 Sept; 19(5): 758-64. PMID:23711418

Rimmer E, Jamieson MA, James PD
Malposition and Expulsion of the Levonorgestrel Intrauterine System Among Women with Inherited Bleeding Disorders. 
Haemophilia 2013 Nov; 19(6): 933-8. PMID: 23711358

Holden R, Tuttle A, Burbidge T, Hegadorn C, Grabell J and James PD. 
Quantitative and qualitative changes of von Willebrand factor and their impact on mortality in patients with end stage kidney disease. 
Blood Coag & Fibrin 2013 Oct; 24(7): 719-26. PMID: 23846000

Rydz N, Swystun L, Notley C, Paterson A, Riches J, Boonyarat B, Montgomery RR, James PD, Lillicrap D. 
The C-type lectin receptor CLEC4M (L-SIGN) binds to, internalizes and contributes to the clearance of von WIllebrand factor and variation in plasma von Willebrand factor levels. 
Blood 2013 Jun 27; 121(26): 5228-37. PMID: 23529928       

 

Berntorp E, Fuchs B, Makris M, Montgomery R, Flood V, O’Donnell JS, Federici AB, Lillicrap D, James PD, Budde U, Morfini M, Petrini P, Austin S, Kannicht C, Jiminez-Yuste V, Lee C. 
Third Aland islands conference on von Willebrand disease, 26 – 28 September 2012: meeting report. 
Haemophilia. March 19, 2013; Suppl 3:1-18. PMID 23383607.

James PD and Lillicrap D. 
The molecular characterization of von Willebrand disease: Good in parts. 
Brit J Haem 2013 Apr: 161(2): 166-76.  PMID 23406206.

Bowman M, Tuttle A, Notley C, Brown C, Tinlin S, Deforest M, Leggo J, Blanchette VS, Lillicrap D, James P for the Association of Hemophilia Clinic Directors of Canada. The Genetics of Canadian Type 3 von WIllebrand Disease (VWD): Further Evidence for Co-dominant Inheritance of Type 3 VWD Alleles. 
J Thromb Haemost 2013 Mar; 11(3): 512-20. PMID 23311757

James PD, Kasthuri R, Kruse-Jarres R, Soni A, Kulkarni R, Dolan G. Global Emerging HEmophilia Panel (GEHEP):
A Multinational Collaboration for Advancing Hemophilia Research and Treatment. 
Transfusion Medicine and Hemotherapy, 2013 Oct;40(5):352-5. [Epub 2013 Aug 26] PMID: 24273489

James PD, Lillicrap DP and Mannucci PM. 
Alloantibodies in von Willebrand Disease.
 
Blood. 2013 Aug 1;122(5):636-40. Epub 2013 Jan 7. Review.PMID: 23297130

James P. Bleeding assessment tools.
Japanese Journal of Thrombosis and Hemostasis 01/2013; 24(6):670-674.

Rydz N and James PD
The Evolution and Value of Bleeding Assessment Tools. 
J Thromb Haemost 2012: 10: 2223-2229. PMID: 22974079.

Rydz N and James PD
Approach to the diagnosis and management of common bleeding disorders.
 
Sem Thromb Haemost 2012; 38: 711-719. PMID: 22941792

James PD and Coller B. 
Phenotyping Bleeding.
 
Current Opinion in Hematology 2012, 19:406-412. PMID: 22759628 


James PD, Lillicrap D.  
von Willebrand Disease:  Clinical and Laboratory Lessons Learned from the Large von Willebrand Disease Studies. 
Am J Hematol 2012 Feb 8, doi: 10.1002/ajh.23142 Epub ahead of print PMID: 22389132

Rydz N and James PD.  
Why is my patient bleeding or bruising? 
Hematol Oncol Clin N Am 2012 (26); 321-344.

Federici AB, James PD.  
Current management of patients with severe von Willebrand disease type 3: a 2012 update.  
Accepted by Haematologica, February 2012.

Sanders S, Purcell S, Silva M, Palerme S, James PD.  
Relationship between diagnosis and intervention in women with inherited bleeding disorders and menorrhagia.  
Haemophilia, 2012 Jan 5, doi: 10.1111/j.1365-2516.2011.02740.x Epub ahead of print PMID: 22221914

Goodeve A, James P
von WIllebrand Disease (October 2011) in: GeneReviews at GeneTests: Medical Genetics Information Resource. 
Available at http://www.genetests.org. PMID: 20301765

Robertson, JD, Yenson PR, Rand ML, Carcao M, Blanchette VS, Lillicrap D, James PD
Expanded Phenotype-Genotype Correlations in a Pediatric Population with Type 1 von Willebrand Disease. 
J Thromb Hamost 2011; 9:1752-1760

James P and Lillicrap D. 
The Diagnosis and Management of von Willebrand Disease in Canada. 
Semin Thromb Hemost 2011; 37: 522-527

James P and Lillicrap D.
The Diagnosis and Management of von Willebrand Disease in Canada. 
Accepted by Seminars in Thrombosis and Haemostasis. January 2011.

James P and Goodeve A.
von Willebrand Disease. 
Genetics in Medicine 2011 May; 13(5): 365-376. PMID 21289515 

Levac B, Parlow J, vanVlyman J, James P, Tuttle A, Shepherd L. 
Ringer’s Lactate is Compatible with SAGM Preserved Packed Red Blood Cells for Rapid Transfusion. 
Can J Anaesth 2010; 57(12): 1071- 1077.

Darwish H, Mundell G, Engen D, Lillicrap D, Silva M and James PD
Early Intraoperative Blood Collection Does Not Affect CBCs, VWF or FVIII Levels in Normal Children. 
J Ped Hematol Oncol 2011; 33(1): 47 - 49. 

Othman M, Chirinian Y, Brown C, Notley C, Hickson N, Hampshire D, Buckley S, Waddington S, Parker A, Baker A, James P, Lillicrap D. 
Functional characterization of a 13 bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. 
Blood 2010; 116: 3645-52. 

Rodeghiero F, Tosetto A, Abshire T, Arnold D, Coller B, James P, Neunert C and Lillicrap D on behalf of the ISTH/SSC Joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. 
ISTH/SSC Bleeding Assessment Tool: A Standardized Questionnaire and a Proposal for a New Bleeding Score for Inherited Bleeding Disorders. 
J Thromb Haemost 2010; 8: 2063-5.

James P and DiPaola J.
The Application of Genetics to Inherited Bleeding Disorders. 
Haemophilia 2010; 16 (Suppl 5):1-5. 

Hickson N, Hampshire D, Winship P, Goudemand J, Schneppenheim R, Budde U, Castaman G, Rodeghiero F, Federici A, James P, Peake I, Eikenboom J, Goodeve A on behalf of EU-VWD and ZPMCB-VWD Study Groups. 
Von Willebrand Factor Variant p.Arg924Gln Marks an Allele Associated with Reduced von Willebrand Factor and Factor VIII Levels. 
J Thromb Haemost 2010; 8:1986-93.

Biss TT, Blanchette VS, Clark DS, Wakefield C, James PD and Rand ML. 
Use of a quantitative Pediatric Bleeding Questionnaire to assess mucocutaneous bleeding symptoms in children with a platelet function disorder. 
J Thromb Haemost 2010; 8:1416-1419. 

Biss TT, Blanchette VS, Clark DS, Bowman M, Wakefield C, Silva M, James PD and Rand ML. 
Quantitation of Bleeding Symptoms in Children with von Willebrand Disease (VWD): Use of a Standardized Pediatric Bleeding Questionnaire. 
J Thromb Haemost 2010; 8:950-956.

M. Bowman, W.M. Hopman, D. Rapson, D. Lillicrap and P. James
The Prevalence of Symptomatic VWD in Primary Care Practice. 
J Thromb Haemost 2010; 8:213-216.

M. Bowman, W.M. Hopman, D. Rapson, D. Lillicrap, M. Silva, and P. James
A Prospective Evaluation of the Prevalence of Symptomatic von Willebrand Disease (VWD) in a Pediatric Primary Care Population. 
Pediatric Blood & Cancer 2010; 55:171-173. 

 

Chapters/Monographs:

Rydz N and James PD. 
von Willebrand Factor and von Willebrand Disease. 
Hoffman, Hematology 6e, Elsevier, 2011.

James PD, Tosetto A. 
Clinical Aspects of von Willebrand Disease: Bleeding History. 
Chapter in von Willebrand Disease: Basic and Clinical Aspects. Wiley-Blackwell 2011.

James PD, Lillicrap D. 
Von Willebrand Disease: an Introduction for the Primary Care Physician, Treatment of Hemophilia Monographs.
The World Federation of Hemophilia, January 2009, No. 47.

James PD, Lillicrap D. 
The Role of Molecular Genetics in Diagnosing von Willebrand Disease. 
Chapter in Seminars in Thrombosis and Hemostasis 2008 Sept; 34(6): 502-8.

James PD, Lillicrap D. 
Von Willebrand Factor. 
Chapter in Mechanisms in Hematology, Core Health Services Inc, Concord Ontario, 2008.

James PD, Lillicrap D. 
Molecular Diagnostic Approaches to Bleeding Disorders and Thrombophilia. 
Textbook chapter for Practical Hemostasis and Thrombosis, Blackwell Science, 2005.


Peer-Reviewed Abstracts (last 5 years): 

Casey L, Bowman M, Soundarya S, James P
Abnormal Angiogenesis in Type 2A and 2B von Willebrand Disease (VWD): Comparative Studies of Quantitative and Qualitative VWD using Blood Outgrowth Endothelial Cells
Submitted to ISTH 2015 Congress

Albanez S, Swystun L, Sponagle K, Grabell J, Brown C, James P, Lillicrap D
Evaluation of Age and Glycan-Related Changes on von Willebrand Factor (VWF) Clearance in a VWF Deficient Mouse Model
Submitted to ISTH 2015 Congress

Xi M, Blanchette V, Blatny J, Collins P, Dunn A, Fischer K, Hermans C, Navarro-Ruan T, Kavakli K, Jackson S, James P, Mammen S, Morfini M, Neufeld E, Ozele M, Radossi P, Rangarajan S, Ruiz-Saez A, Teitel J, Thabane L, Young G, Iorio A and on behalf of the WAPPS Investigators
Pharmacokinetic Characteristics of Factor VIII and IX Concentrates- A Systematic Review
Submitted to ISTH 2015 Congress

Iorio A, Blanchette V, Blatny J, Collins P, Crouteau S, Dunn A, Fischer K, Hermans C, Kavalki K, Jackson S, James P, Mammen S, Morfini M, Navarro-Ruan T, Neufeld EJ, Ozelo M, Radossi P, Rangarajan S, Ruiz-Saez A, Teitel J, Thabane L, Young G, Xi M
A Population Approach to Hemophilia Pharmacokinetics. WAPPS: A Web-Service for Bayesian Post Hoc Estimation
Submitted to ISTH 2015 Congress

Xu Y, Deforest M, Grabell J, Hopman W, James P
Health-related quality of life among von Willebrand Disease patients is not related to disease severity
Submitted to ISTH 2015 Congress

Young J, Grabell J, Rydz N, Hopman W, Good D, Mahlangu J, James P
Relationship between quality of life and coagulation factor level in Hemophilia Carriers:  Preliminary Results
Submitted to ISTH 2015 Congress

James PD, Bidlingmaier C, Mingot-Castellano ME, Chitlur M, Fogarty PF, Grabell J, Mathew P, Mahlangu P and Global Hemostasis Experts Panel (GEHEP)
Validation of the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (ISTH-BAT) in Hemophilia Carriers
Submitted to ISTH 2015 Congress

Tuttle A, Grabell J, Bae S, Moorehead P, Blanchette V, Wu J, Steele M, Klaasen R, Silva M, Rand ML, James PD
Validation of the Self-PBQ (Self-Administered Pediatric Bleeding Questionnaire) as a Screening Tool for a new Diagnosis of von Willebrand Disease (VWD)
Submitted to ISTH 2015 Congress

Swystun LL, Notley C, Georgescu I, Sponagle K, Schledzewski K, Geraud C, Kzhyshkowska J, Goerdt S, James PD, Lillicrap D
The scavenger receptor stabilin-2 (STAB-2) mediates clearance of human von Willebrand factor and factor VIII by liver sinusoidal endothelial cells
Submitted to ISTH 2015 Congress

Webster S, Hampshire D, Theophilus B, Schneppenheim R, Bellissimo D, James PD, Peake I, Goodeve A
Detection of Large Exonic and Intergenic Deletions in the VWF Locus using Array Comparative Genomic Hybridisation (aCGH)
Submitted to ISTH 2015 Congress

Hawke L, Rivard G, James P
Identification and Characterization of Aberrant Splicing from a Novel Branch Site Mutation in von Willebrand Factor
Submitted to ISTH 2015 Congress

Albánez S, Ogiwara K , Grabell J , James P , Lillicrap D
Aging and ABO Blood Type Regulate von Willebrand Factor and Factor VIII Levels through Distinct Patterns of both Secretion and Clearance
Submitted to ISTH 2015 Congress

Bidlingmaier C, Mahlangu J, James P,
Global Emerging Hemophilia Panel (GEHEP). Validation of the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (ISTH-BAT) in haemophilia carriers
Accepted to 59th Annual Meeting of the Society of Thrombosis and Hemostasis Research (GTH), Düsseldorf, Germany February, 2015.

Bowman M, Casey L, Tuttle A, James PD
Distinct cellular VWF phenotypes observed in BOEC from type 3 VWD patient with VWF propeptide mutations compared to non-propeptide mutations.
Accepted to 8th Bari International Conference, Bari, Italy, October, 2014.

Pruss CM, Barr S, Grabell J, Tinlin S, Tuttle A, Adams MA, Garland JS, James PD and Holden RM. von Willebrand Factor Synthesis and Circulating Half Life are Progressively Elevated, but Relative Platelet Binding Decreases in stage 3-5 Chronic Kidney Disease Patients.
Accepted to Canadian Hypertension Congress, October 2014

Pruss CM, Barr S, Tuttle A, Grabell J, Tinlin S, Adams MA, Hopman WM, Garland JS, James PD and Holden, RM. 
Stage 3-5 CKD patient coronary artery calcification status correlates positively with von Willebrand Factor platelet binding.
Accepted to ASN Kidney Week, 2014.

Albanez S, Ogiwara K, Grabell J, James P, Lillicrap D.
Association Between von Willebrand Factor and Factor VIII Levels and their Changes During the Aging Process.
J Thromb Haemost 2014 June; 12 (Suppl 1): 2014.

Albanez S, Ogiwara K, Grabell J, James P, Lillicrap D.
Age-Related Changes to the Mechanisms Responsible for Regulating Plasma Levels of von Willebrand Factor and Factor VIII.
Thrombosis Research 2014 May; 133 (Suppl 3): S31.

Tuttle A, Grabell J, Clark DS, Moorehead P, Blanchette VS, Wu J, Steele M, Klaasen R, Silva M, Rand ML, James PD. 
Item Reduction Analysis of the Self-PBQ (Self-Administered Pediatric Bleeding Questionnaire): Healthy Children and Children Previously Diagnosed with Type 1 von Willebrand Disease (VWD).
J Thromb Haemost 2014 June; 12 (Suppl 1): PHT03.

Casey, L, Bowman M, Umana B, Maurice D, James PD.
Patient-Derived Blood Outgrowth Endothelial Cells from a Type 2B von Willebrand Disease Patient Exhibit Increased Angiogenesis.
J Thromb Haemost 2014 June; 12 (Suppl 1): VWF04.

Deforest M, Grabell J, Hopman W, James PD.  The Self-BAT (Self-administered Bleeding Assessment Tool) is an Effective Screening Tool for von Willebrand disease in Women Referred to Hematology.
Haemophilia 2014;20(Suppl 3): 183.

Young J, Grabell J, Tuttle A, Deforest M, Good D, Rydz N, Mahlangu J, Hopman W, James PD.  Validation of the Self-BAT (Self-administered Bleeding Assessment Tool) in Hemophilia Carriers: Preliminary Results. 
Haemophilia 2014;20(Suppl 3): 7.

Kaur H, Assam H, Ozelo M, Scovil S, James PD, Othman M. 
Assessment of bleeding phenotype in PT-VWD and other RBDs using the electronic bleeding questionnaire (eBQ): a retrospective study on 55 subjects. 
Haemophilia 2014; 20(Suppl 3): 108.

Hawke L, Rivard G-E, Poon M-C, James PD. 
Characterization of VWF Splice Variants from Exonic and Intronic Splicing Mutations. 
Blood (ASH Annual Meeting Abstracts), Oct 2013; 122: 21, 1069.

Swystun L, Notley C, Georgescu I, James PD, Lillicrap D. 
The Endothelial Lectin Receptor CLEC4M Internalizes Factor VIII and VWF Via a Clathrin-Coated Pit-Dependent Mechanism. 
Blood (ASH Annual Meeting Abstracts), Oct 2013; 122: 21, 1091.

Elbatarny M, Mollah S, Grabell J, Rand ML, Clark D, Mauer A, Christopherson P, Montgomery R, Zimmerman Program Investigators, Coller B, James PD. 
Normal Range of Bleeding Scores for the ISTH-BAT: Adult and Pediatric Data From the Merging Project. 
Blood (ASH Annual Meeting Abstracts), Oct 2013; 122: 21, 1107.

Swystun L, Notley C, Sponagle K, James PD, Lillicrap D. 
Regulation of Factor VIII Clearance by Mannose-Binding Lectins. 
Blood (ASH Annual Meeting Abstracts), Oct 2013; 122: 21, 2340.

Bowman M, Casey L, Hawke L, James PD. 
Heterogeneity of Type 3 VWD: Evidence from Patient-Derived Blood Outgrowth Endothelial Cells (BOEC). 
Blood (ASH Annual Meeting Abstracts), Oct 2013; 122: 21, 3517.

Michels A, Albanez S, Swystun L, Sponagle K, James PD, Lillicrap D. 
Association of cell-free DNA with plasma von WIllebrand factor levels in human and mouse models of inflammation. 
J Thromb Haemost, 2013; 11(Suppl 2), OC 85.5.

Hawke L, Poon M-C, Scully M-F, James PD.
Alterations in aberrant and endothelial splicing of von Willebrand factor under high laminar shear stress.
J Thromb Haemost, 2013; 11(Suppl 2), PB 1.44-1.

Rand M, Tuttle A, Grabell J, Moorehead P, Deforest M, Wu J, Steele M, Klaassen R, Silva M, James PD.  Development of the Self-PBQ (Self-administered Pediatric Bleeding Questionnaire): Pre-testing and optimization. 
J Thromb Haemost, 2013; 11(Suppl 2), PA 1.09-6.

Bowman M, Casey L, Morrison L, Tuttle A, Walker I, Silva M, Jacobi P, Haberichter S, Lillicrap D, James PD. 
Investigation of the contribution of VWF propeptide mutations to Type 3 VWD using in vitro cellular studies and patient-derived BOEC. 
J Thromb Haemost, 2013; 11(Suppl 2), OC 39.5.

Mollah S, Rand M, Clark DS, Christopherson P, Mauer A, Montgomery RR, Zimmerman Program Investigators, Coller B, James PD.  The Merging Project: 
A Machine Learning Approach to Merge and Analyze Data from Four Different Bleeding Questionnaires. 
J Thromb Haemost, 2013; 11(Suppl 2), PA 2.08-2.

Swystun L, Notley C, Sponagle K, James PD, Lillicrap D. 
The endothelial lectin CLEC4M is a novel clearance receptor for Factor VIII. 
J Thromb Haemost, 2013; 11(Suppl 2), OC 05.6.

Albanez S, Michels A, Sponagle K, Grabell J, James PD, Lillicrap D. 
An evaluation of the age-related quantitative and qualitative pathophysiology of VWF. 
J Thromb Haemost, 2013; 11(Suppl 2), PB 1.44-3.

Moorehead P, Thibeault L, Tuttle A, Grabell J, Dwyre L, Silva M, James PD, Lillicrap D. 
Rapid Immune Tolerance Induction Following Early Primary Immunologic Prophylaxis in a Hemophilia A Patient with High-Titre Inhibitor. 
J Thromb Haemost, 2013; 11(Suppl 2), PO 153.

Swystun L, Rydz N, Notley C, Riches J, Paterson AD, Montgomery RR, James PD, Lillicrap D. 
Genetic Variability of the CLEC4M Endothelial Lectin Receptor Modulates Binding and Internalization of Von Willebrand Factor and Contributes to Variance in Plasma VWF Levels
Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 16.

Rimmer E, Jamieson MA, James PD.
Rates of Malposition and Expulsion of Levonorgestrel Intrauterine System Among Women with Inherited Bleeding Disorders in a Canadian Centre. 
Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 3367.

Bowman M, Ling L, Pluthero F, Christensen H, Walker I, Kahr W, James PD. 
Comparative Cellular Studies of the VWF Exon 4-5 Deletion Mutation Using Patient-Derived BOEC (Blood Outgrowth Endothelial Cells) and Megakaryocytes. 
Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 1076.

Hawke L, Scully M-F, James PD.
In Vitro and Ex Vivo Investigation of Aberrant and Alternative Splicing of von Willebrand Factor. 
Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 2179.

Labarque V, Blanchette V, Clark DS, James PD, Rand ML. 
Prospective comparison of the pediatric bleeding questionnaire (PBQ) and ISTH-BAT in children referred to a tertiary-care pediatric centre. 
Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 2229.

Demers C, James P, Winikoff R. 
Hemostatic changes during pregnancy in healthy women and in women with inherited bleeding disorders. 
Haemophilia 2012; 18: Suppl 3 PO-MO-266.

Deforest M, Grabell J, Tuttle A, Thibeault L, Hopman W, James P. 
Generation and Optimization of the Self-Administered Bleeding Assessment Tool (Self-BAT).
Haemophilia 2012; 18: Suppl 3 FP-TU-04.3-4.

Rydz N, Leggo J, Tinlin S, James P, Lillicrap D and the AHCDC. 
The Canadian “National Program for Hemophilia Mutation Testing” database: a ten-year anniversary review. 
Haemophilia 2012; 18: Suppl 3 PO-MO-153.

Rydz N, Grabell J, Lillicrap D and James P. 
Changes in von WIllebrand factor level and activity with age in Type 1 von Willebrand disease. 
Haemophilia 2012; 18: Suppl 3 PO-MO-249.

Segbefia CI, Biss TT, Clark DS, James PD, Blanchette VS, Rand ML. 
Identification of Children with Significant Epistaxis: Comparison of the Katsanis et al Epistaxis Scoring System and the Pediatric Bleeding Quesitonnaire Epistaxis Score. 
ISTH Kyoto 2011 P-WE-552.

Albanez S, Grabell J, Burnett E, Sponagle K, James PD, Lillicrap D. 
Increased VWF Levels in Later Life are Associated with Evidence of Both Enhanced Biosynthesis and Reduced Clearance. 
ISTH Kyoto 2011 P-MO-444.

Rydz N, Boonyawat B, Riches J, Hopman W, Paterson A, Montgomery R, Lillicrap D, James PD. 
Genetic variability of the CLEC4M Endothelial Lectin Receptor in Type 1 von Willebrand Disease. 
ISTH Kyoto 2011 O-MO-137.

James PD, Biss TT, Clark DS, Grabell J, Riddel J, Silva M, Rapson D and Rand ML. -1 to +4 vs. 0 to +3?: 
Comparing scoring systems for bleeding symptoms in the Condensed MCMDM-1 VWD and the Pediatric Bleeding Questionnaires. 
ISTH Kyoto 2011 P-MO-455.

James P, Bowman M, Grabell J, Dwyre L, Rapson D. 
Prospective Validation of the Condensed MCMDM1-VWD Bleeding Questionnaire for Platelet Function Disorders. 
ISTH Kyoto 2011 P-WE-092.

Jackson S, Poon M-C, Grabell J, Lillicrap D and James P.
The Condensed MCMDM-1 VWD Bleeding Questionnaire: Utility as a Diagnostic Tool in the Hematology Clinic. 
ISTH Kyoto 2011 P-TU-459.

Segbefia CI, Biss TT, Clark DS, James PD, Riddel J, Blanchette V, Rand M. 
Evaluation of the severity and pattern of epistaxis in children with a mucocutaneous bleeding disorder and in healthy children using a standardized questionnaire.
Blood (ASH Annual Meeting Abstracts), Nov 2010; 116:713.

Holden R, Tuttle A, MacLeod F, Burbidge T, Hegadorn C and James PD.
Association of Quantitative and Qualitative Abnormalities of von Willebrand Factor and Risk of Death in Hemodialysis Patients. 
Blood (ASH Annual Meeting Abstracts), Nov 2010; 116:2217.

Holme PA, James P, Gomez K, Fogarty P on behalf of the Global Emerging Hemophilia Experts Panel (GEHEP). 
Variation in International Practices for the Peri-operative Management of Major Surgery for Persons with Severe Hemophilia. 
Haemophilia 2010, 16 (Suppl 4), 06P21.

S. Purcell, S. Sanders, M. Silva, S. PalermeP. James
Implementation of a Women and Bleeding Disorders Clinic: Enhancing the Comprehensive Care Model. 
Haemophilia 2010, 16 (Suppl 4), 04P26.